Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease
Efficacy and Safety of Dulaglutide, SGLT-2 Inhibitors, and Finerenone Triple Therapy in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease: A Multicenter, Prospective, Randomized Controlled Study
Sponsor: First Affiliated Hospital of Wannan Medical College
Listed as NCT07537088, this observational or N/A phase trial focuses on CKD - Chronic Kidney Disease and T2DM (Type 2 Diabetes Mellitus) and remains actively recruiting participants. Sponsored by First Affiliated Hospital of Wannan Medical College, it has been updated 2 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
2 versions recorded-
Apr 23, 2026 — Present [daily]
Not Yet Recruiting
-
Apr 18, 2026 — Apr 23, 2026 [daily]
Not Yet Recruiting
First recorded
Eligibility Summary
The purpose of this study is to evaluate whether adding dulaglutide to the combination therapy of Sodium-Glucose Co-Transporter 2 Inhibitors(SGLT2i) and finerenone can provide additional kidney protection and safety for Chinese adults with Type 2 Diabetes Mellitus(T2DM) and Chronic Kidney Disease(CKD). Eligible participants will be adults with T2DM and mild-to-moderate CKD who have been receiving SGLT2 inhibitor plus finerenone for at least 3 months on the basis of maximum tolerated dose of renin-angiotensin system inhibitor (RASi). Participants will be randomly assigned to either continue the original regimen or to receive add-on therapy with dulaglutide.The study will last for 26 weeks, with participants required to attend scheduled visits for efficacy and safety assessments at Week 13 (±1 week) and Week 26 (±1 week, final visit).
Contact Information
- First Affiliated Hospital of Wannan Medical College
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.